Exhibit 99
                                                                      ----------

================================================================================

Paul A. Rosinack                                  Michael K. Green
President and CEO                                 Sr. Vice President and CFO
858-451-3771 x1401                                858-451-3771 x1407
paul@synbiotics.com                               mikeg@synbiotics.com
- -------------------                               --------------------

================================================================================

                 Synbiotics Corporation Receives $2.8 Million in
                   Equity Financing and Restructures Bank Debt

San Diego, California: January 25, 2002 -- Synbiotics Corporation (OTCBB: SBIO)
today announced that it has completed a $2.8 million convertible preferred
equity financing with Redwood West Coast, LLC, a private investment firm based
in Cincinnati, Ohio. In conjunction with the equity financing, forty-one
Synbiotics employees converted approximately $1.5 million of contractual
stay-bonus payments due them into shares of Synbiotics common stock. Following
the financing, Redwood will own approximately 54 percent and the employees will
own approximately 21 percent, on an as converted basis, of the outstanding
shares of Synbiotics common stock.

Synbiotics also announced that it has restructured the terms of its debt with
Comerica Bank. Under the amended Comerica Agreement, the prior line of credit
and term debt totaling $7.1 million due in March, 2002 has been consolidated
into a single $7.1 million term loan. The new term loan will involve minimal
financial covenants and is due in January, 2004.

Paul A. Rosinack, President and CEO of Synbiotics, said, "The Redwood and
Comerica transactions complete the restructuring program begun in 2000 and will
enable the Company to return its focus to day-to-day business issues. These
transactions, coupled with cash flow from business operations, should enable
Synbiotics to be self-sustaining, profitable and to return to a growth track."
Rosinack also noted that Synbiotics was no longer seeking opportunities to be
acquired.

Synbiotics Corporation develops, manufactures and markets veterinary
diagnostics, instrumentation and related products for the companion animal,
large animal and poultry markets worldwide. Headquartered in San Diego,
California, Synbiotics manufactures and distributes its products through its
operations in San Diego, CA, Rome, NY, and Lyon, France. For information on
Synbiotics and its products, visit the Company's website at www.synbiotics.com.

With the exception of historical matters, the issues discussed in this press
release are forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those
anticipated in the forward-looking statements. These risks and uncertainties
include competition from larger companies, reliance on third-party manufacturers
and distributors, possible technology improvements by others, the seasonality of
major portions of the Company's business and other risks set forth in Synbiotics
Corporation's filings with the Securities and Exchange Commission, particularly
Form 10-K filed for the year ended December 31, 2000 and subsequent Form 10-Q
filings. These forward-looking statements represent Synbiotics Corporation's
judgment as of the date of the release. Synbiotics Corporation disclaims,
however, any intent or obligation to update these forward-looking statements.